RedHill, Temple University deal
RedHill said it acquired rights from the university to IP covering the company's RHB-102. In 2010, RedHill licensed patents from the now defunct Scolr Pharma Inc., which had licensed those patents from the university. RedHill said the deal with the university is under similar financial terms as the deal with Scolr, which has been terminated, but RedHill declined to disclose details. Under the 2010 deal, Scolr was eligible to receive up to $600,000 in upfront and milestone payments, plus up to $30 million over 10 years in royalties (see BioCentury, May 17, 2010).
RedHill also announced that an NDA for RHB-102 to prevent nausea and vomiting in cancer patients will not be submitted this quarter as planned. The company held a pre-NDA meeting with FDA, and the company has provided the agency with additional information and is awaiting the FDA's response. RedHill said it will provide updated guidance on the submission "as soon as sufficient regulatory clarity is obtained." Last year, RedHill delayed by a quarter to 1Q14 the submission to obtain "additional CMC information" (see BioCentury, March 4, 2013 & July 29, 2013). ...